Novembre 17-18th, 2020 : Defymed is looking forward to participate to the «Fall Beta Cell Replacement Consortium» virtual meeting organized by the JDRF foundation. The aim is to provide a global network of top notch researchers and industry leaders to accelerate and advance strategic areas in the cell therapy and encapsulation to treat type 1 diabetes (T1D). It also aims to identify major gaps and discuss potential strategies to support gap-filling initiatives. The consortium exists to foster collaboration, incorporate novel concepts, address technical challenges and limitations, support reagent sharing and protocol standardization, and with support from the JDRF regulatory team, build a robust technology pipeline that brings life-changing therapies to people living with T1D.

Séverine Sigrist (CEO), Elisa Maillard-Pedracini (CSO) and Richard Bouaoun (COO) will be participating to this meeting.
For more info about the consortium initiative